Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUSICA-2: Fruquintinib + Sintilimab in Advanced Renal Cell Carcinoma
NCT05522231Phase 3Completed
- Sponsor
- HUTCHMED
- Start
- Oct 2022
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fruquintinib in renal cell carcinoma (RCC) (3 arms), sponsored by HUTCHMED. Primary endpoints: Progression Free Survival in Part I at 20 months and Objective Response Rate in Part II at 20 months. Started Oct 2022; status: completed.
02
Drugs
fruquintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05522231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522231.